Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Pathway”

27 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 27 results

Testing effectiveness (Phase 2)Study completedNCT02285439
What this trial is testing

Study of MEK162 for Children With Low-Grade Gliomas

Who this might be right for
Low-Grade GliomasMalignant Neoplasms, BrainSoft Tissue Neoplasms
Children's Hospital Los Angeles 105
Early research (Phase 1)Looking for participantsNCT07318324
What this trial is testing

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Who this might be right for
Phase IBAvutometinibRAS Pathway+1 more
M.D. Anderson Cancer Center 31
Testing effectiveness (Phase 2)Study completedNCT05340621
What this trial is testing

NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)

Who this might be right for
RAS MutationNRAS Gene MutationMelanoma
OnKure, Inc. 36
Early research (Phase 1)Ended earlyNCT07121829
What this trial is testing

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

Who this might be right for
MelanomaSolid TumorPilocytic Astrocytoma+7 more
Day One Biopharmaceuticals, Inc. 44
Early research (Phase 1)Ended earlyNCT06287463
What this trial is testing

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Who this might be right for
Advanced Solid TumorRAF MutationRAS Mutation+7 more
Deciphera Pharmaceuticals, LLC 29
Testing effectiveness (Phase 2)Study completedNCT00098254
What this trial is testing

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

Who this might be right for
Non-Small-Cell Lung Carcinoma
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)WithdrawnNCT06284460
What this trial is testing

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Who this might be right for
Pathway Mutant Myelodysplastic SyndromesMyelodysplastic NeoplasmMyeloproliferative Neoplasm
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Ended earlyNCT04198818
What this trial is testing

Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Who this might be right for
Advanced TumorsMelanomaNon-Small-Cell Lung Cancer+2 more
Haihe Biopharma Co., Ltd. 37
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Testing effectiveness (Phase 2)Ended earlyNCT03504501
What this trial is testing

Synaptic Plasticity and Cognitive Function in RASopathies

Who this might be right for
Impaired Synaptic PlasticityImpaired Cognition
Technical University of Munich 16
Testing effectiveness (Phase 2)Study completedNCT02399943
What this trial is testing

A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer

Who this might be right for
Colorectal CancerKRAS WildtypeNRAS Wildtype+1 more
University Health Network, Toronto 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT04409639
What this trial is testing

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

Who this might be right for
Chronic Myelomonocytic Leukemia (CMML)
University of Utah 14
Not applicableLooking for participantsNCT04888936
What this trial is testing

Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies

Who this might be right for
Costello SyndromeNoonan SyndromeCardiofaciocutaneous Syndrome+3 more
National Cancer Institute (NCI) 500
Testing effectiveness (Phase 2)Ended earlyNCT03002623
What this trial is testing

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Who this might be right for
Thyroid NeoplasmsPoorly Differentiated and Undifferentiated Thyroid CancerDifferentiated Thyroid Cancer
National Cancer Institute (NCI) 7
Early research (Phase 1)Ended earlyNCT04892017
What this trial is testing

Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
Deciphera Pharmaceuticals, LLC 91
Testing effectiveness (Phase 2)Study completedNCT01885195
What this trial is testing

MEK162 for Patients With RAS/RAF/MEK Activated Tumors

Who this might be right for
Solid Tumor and Hematologic Malignancies
Pfizer 110
Early research (Phase 1)Looking for participantsNCT06326411
What this trial is testing

Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Who this might be right for
OncologyMEK MutationRAF Gene Mutation+6 more
Nested Therapeutics, Inc 230
Testing effectiveness (Phase 2)Ended earlyNCT03705507
What this trial is testing

International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, Pediatric+2 more
University of Birmingham 12
Early research (Phase 1)Looking for participantsNCT06299839
What this trial is testing

PAS-004 in Patients With Advanced Solid Tumors

Who this might be right for
RAS MutationNF1 MutationRAF Mutation+1 more
Pasithea Therapeutics Corp. 48
Not applicableUnknownNCT03401957
What this trial is testing

The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment

Who this might be right for
Colorectal CancerDrug ResistanceMass Spectrometry+1 more
National Health Research Institutes, Taiwan 120
Next Page